Active Biotech: Slumps by a third after key trial update

Active Biotech AB publ

31/07/2018 09:31

** Shares in Sweden's Active Biotech  ACTI.ST  slump >36 pct
after providing update on laquinimod in Huntington's disease
 urn:newsml:reuters.com:*:nGNE8fpLBT
    ** Co says Phase 2 LEGATO-HD trial evaluating the safety and
efficacy of laquinimod as a treatment in Huntington's disease
(HD) did not meet its primary endpoint 
    ** Primary endpoint evaluated the change from baseline at
month 12 in the UHDRS-TMS for the 1.0 mg dose as compared to
placebo
    

 ((marta.frackowiak@tr.com))